Latest research on Sevelamer

Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.

Latest findings

His regular medications included Irbesartan 150 mg once a day, Amlodipine 5 mg once a day, Simvastatin 20 mg once a day, alfacalcidol 0.25 microgram once a day and Sevelamer 800 mg three times a day with meals. [source, 2016]
None of the phosphate binders, except Sevelamer, was associated to the value of serum Calcium. [source, 2016]
Patients on Sevelamer show serum Calcium levels slightly higher than patients not taking Sevelamer. [source, 2016]
This may reflect the fact that Sevelamer was given to patients with high Calcium to avoid Calcium containing Calcium binders. [source, 2016]
Serum P level was associated to the use of phosphate binders: Calcium binders, Sevelamer and lanthanum without significant differences among the phosphate binders [source, 2016]
Calcium-free binders (Sevelamer hydrochloride, Sevelamer carbonate, lanthanum carbonate) are equally or slightly less effective than calcium-based binders and their use does not seem to be associated with high calcium levels: this would reduce the risk for vascular calcifications. [source, 2016]
Sevelamer carbonate may cause gastrointestinal adverse events including nausea, vomiting, dyspepsia, abdominal pain, and changes in bowel habits. [source, 2016]
Bixalomer seems to effectively reduce phosphatemia with fewer gastrointestinal symptoms compared to Sevelamer hydrochloride. [source, 2016]
An example is Genz-644470, a polymer showing the ability to effectively reduce serum phosphate in hemodialysis patients but with no advantages over Sevelamer carbonate.44 [source, 2016]
Later, a Phase II, randomized, active-controlled, multi-center, open-label, dose-finding study (NCT00824460) was designed to evaluate efficacy and safety of different dosages of sucroferric oxyhydroxide (1.25, 5.0, 7.5, 10.0, or 12.5 g/day) as compared to Sevelamer hydrochloride (4.8 g/day) for 6 weeks in a cohort of 154 hemodialysis patients. [source, 2016]